---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-002750"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:41:14.181563+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dogwood converts $19.9M debt and interest to Series A-1 preferred equity

## Summary
- $19.5M principal plus accrued interest ($19,926,891 total) exchanged for 284.2638 shares of Series A-1 Non-Voting Convertible Preferred Stock.
- Each preferred share convertible into 10,000 common shares, pending stockholder approval and Nasdaq rules.
- All existing debt removed from balance sheet; company funded through Q4 2025 interim of Phase 2b CINP trial.
- Largest shareholder CK Life Sciences (through Conjoint) facilitated the conversion, signaling confidence in Halneuron program.

## SEC filing metadata
- accession: 0001558370-25-002750
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 3.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837025002750/0001558370-25-002750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837025002750/dwtx-20250312x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-002750
- JSON: https://secwatch.observer/filing/0001558370-25-002750.json
- Plain text: https://secwatch.observer/filing/0001558370-25-002750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.